JCM
PPBT

Jacobi Capital Management’s Purple Biotech PPBT Stock Holding History

Jacobi Capital Management’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1
Closed -$2K – 1292
2020
Q2 		$2K Buy
+1
New +$983 ﹤0.01% 1067

Other funds holding PPBT

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFC
Bedel Financial Consulting Indianapolis, Indiana $1.06B AUM 38.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Jacobi Capital Management's PPBT Position: Q3 2020 in Review

Jacobi Capital Management sold out of Purple Biotech (PPBT) in Q3 2020, closing a stake of 1 share — an estimated $2K sold.

Jacobi Capital Management first reported a position in PPBT in Q2 2020 and held it in 1 quarter. The position peaked at $2K in Q2 2020. 15 funds tracked by Wall St. Rank hold PPBT as of Q3 2020.

  • Jacobi Capital Management reported no remaining Purple Biotech position as of Q3 2020 after selling out during the quarter.
  • Jacobi Capital Management sold 1 Purple Biotech share in Q3 2020, an estimated $2K.
  • Jacobi Capital Management first reported a position in Purple Biotech in Q2 2020 and held it in 1 quarter.
  • Jacobi Capital Management's Purple Biotech position peaked at $2K in Q2 2020.
  • 15 funds tracked by Wall St. Rank held Purple Biotech as of Q3 2020.

Based on Jacobi Capital Management's 13F filing for Q3 2020, filed 30 Oct 2020.